China Pharma Holdings (CPHI) EBIT Margin (2010 - 2026)

China Pharma Holdings has reported EBIT Margin for 17 years, with the latest figure at 113.6% in Q1 2026.

• For the quarter ending Q1 2026, EBIT Margin fell 4683.0% year-over-year to 113.6%; the trailing twelve-month figure through Mar 2026 stood at 28.95% (down 505.0% YoY), and the FY2025 full-year result was 19.23%, up 692.0% from the prior year.
• EBIT Margin for Q1 2026 stood at 113.6%, down from 101.3% in the prior quarter.
• The five-year high for EBIT Margin was 194.77% in Q4 2024, with the low at 150.44% in Q2 2024.
• Historically, EBIT Margin has averaged 29.6% across 5 years, with a median of 48.33% in 2022.
• The largest YoY upside for EBIT Margin was 15767 bps in 2024 against a maximum downside of 10888 bps in 2024.
• China Pharma Holdings' EBIT Margin stood at 48.14% in 2022, then fell by 23 bps to 37.1% in 2023, then jumped by 425 bps to 194.77% in 2024, then sank by 48 bps to 101.3% in 2025, then plunged by 212 bps to 113.6% in 2026.
• The last three EBIT Margin figures came in at 113.6% (Q1 2026), 101.3% (Q4 2025), and 83.06% (Q3 2025), per Business Quant data.